GO:0047102 aminomuconate-semialdehyde dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047102 describes the NAD+-dependent oxidation of 2-aminomuconate semialdehyde to 2-aminomuconate, a reaction in the kynurenine pathway of tryptophan catabolism.
• The enzyme is a tetrameric aldehyde dehydrogenase; correct tetramer assembly is required for NAD+ binding and catalytic activity.
• A conserved 'pitcher-and-catcher' mechanism drives substrate isomerization prior to dehydrogenation, ensuring fidelity in kynurenine metabolism.
• In humans, the enzyme corresponds to ALDH8A1 (ALDH12), which was reassigned from a retinaldehyde dehydrogenase to a kynurenine pathway enzyme.
• Crystallographic and spectroscopic snapshots have captured the enzyme in action, revealing conformational changes during catalysis.
• Dysregulation of this activity affects NAD+/NADH balance and has been linked to neurological and metabolic disorders.
Description
GO:0047102, aminomuconate-semialdehyde dehydrogenase (NAD+) activity, is a molecular function defined by the catalysis of the reaction H2O + NAD+ + 2-aminomuconate semialdehyde = NADH + 2-amino-muconate. This activity is a key step in the kynurenine pathway, the major route of tryptophan degradation in mammals and bacteria. The enzyme belongs to the aldehyde dehydrogenase superfamily and requires NAD+ as an electron acceptor. Understanding this activity is important because it links amino acid catabolism to cellular redox balance and has implications for neurobiology, immunology, and metabolic engineering. Researchers study it to dissect substrate channeling, cofactor specificity, and the role of quaternary structure in catalysis.
aminomuconate-semialdehyde dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0047102 |
|---|---|
| GO term | aminomuconate-semialdehyde dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | 2-aminomuconate-6-semialdehyde:NAD+ 6-oxidoreductase activity; 2-aminomuconate semialdehyde dehydrogenase activity; 2-hydroxymuconate semialdehyde dehydrogenase activity; 2-hydroxymuconic acid semialdehyde dehydrogenase activity; 2-hydroxymuconic semialdehyde dehydrogenase activity; alpha-aminomuconic epsilon-semialdehyde dehydrogenase activity; alpha-hydroxymuconic epsilon-semialdehyde dehydrogenase activity |
| Major function | NAD+-dependent oxidation of 2-aminomuconate semialdehyde to 2-aminomuconate in kynurenine pathway |
| Reaction | H2O + NAD+ + 2-aminomuconate semialdehyde = NADH + 2-amino-muconate |
| Cofactor | NAD+ |
| Enzyme class | Aldehyde dehydrogenase (EC 1.2.1.-) |
| Subunit | Homotetramer (in Pseudomonas pseudoalcaligenes) |
| Human gene | ALDH8A1 (ALDH12) |
What Is GO:0047102?
Aminomuconate-semialdehyde dehydrogenase (NAD+) activity (GO:0047102) is the catalytic function of an enzyme that oxidizes 2-aminomuconate semialdehyde to 2-aminomuconate using NAD+ as the electron acceptor, releasing NADH and water. This reaction is part of the kynurenine pathway, converting an intermediate from tryptophan catabolism into a precursor for further degradation.
Why Is aminomuconate-semialdehyde dehydrogenase (NAD+) activity Important in Cell Biology?
This activity is critical for the kynurenine pathway, which regulates the levels of neuroactive metabolites such as kynurenic acid and quinolinic acid. By controlling the flux of 2-aminomuconate semialdehyde, the enzyme influences NAD+ homeostasis and cellular redox state. Its dysfunction has been associated with neurological disorders and metabolic imbalances, making it a potential therapeutic target.
• Maintains kynurenine pathway flux, affecting neuroactive metabolite production.
• Regulates NAD+/NADH ratio, impacting cellular energy metabolism and redox signaling.
• Mutations or altered expression may contribute to neurodegenerative diseases.
• Provides a model for studying aldehyde dehydrogenase mechanism and substrate specificity.
• Potential target for metabolic engineering of tryptophan catabolism in bacteria.
• Involved in bacterial degradation of aromatic compounds like 2-aminophenol.
• Its tetrameric assembly is essential for cofactor binding, offering insights into protein assembly.
• Can be studied using CRISPR to create knockout or point-mutation cell models for functional analysis.
Molecular Mechanism of aminomuconate-semialdehyde dehydrogenase (NAD+) activity
Substrate Binding and Isomerization
In simple terms: The enzyme grabs the substrate and changes its shape before the chemical reaction.
The enzyme binds 2-aminomuconate semialdehyde and catalyzes its isomerization to a reactive form via a 'pitcher-and-catcher' mechanism, as shown for a related dehydrogenase in kynurenine metabolism. This step ensures that the correct substrate is processed and prevents side reactions.
NAD+ Binding and Tetramer Assembly
In simple terms: The enzyme must be a four-part assembly to hold the NAD+ cofactor properly.
The enzyme functions as a homotetramer, and this quaternary structure is required for efficient NAD+ binding. Disruption of tetramerization reduces catalytic activity, highlighting the importance of assembly for function.
Catalytic Dehydrogenation
In simple terms: The enzyme removes hydrogen from the substrate and transfers it to NAD+.
Following isomerization, the enzyme catalyzes the NAD+-dependent oxidation of the aldehyde to a carboxylic acid, producing NADH and 2-aminomuconate. Crystallographic snapshots have captured conformational changes during this step, revealing a dynamic active site.
Product Release and Cofactor Recycling
In simple terms: The products are released, and NADH is recycled back to NAD+.
After catalysis, NADH and 2-aminomuconate are released, and NAD+ is regenerated through cellular respiration or other redox reactions. The enzyme's activity is tightly linked to the cellular NAD+/NADH ratio.
Key Genes Involved in GO:0047102 aminomuconate-semialdehyde dehydrogenase (NAD+) activity
The following genes and proteins are directly involved in or regulate aminomuconate-semialdehyde dehydrogenase (NAD+) activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH8A1 (ALDH12) | Human enzyme with aminomuconate-semialdehyde dehydrogenase activity | Reassigned to kynurenine pathway; studied in tryptophan catabolism |
| KMO | Kynurenine 3-monooxygenase, upstream of the dehydrogenase | Regulates flux into the pathway |
| KYNU | Kynureninase, produces 2-aminomuconate semialdehyde | Provides substrate for the dehydrogenase |
| HAAO | 3-hydroxyanthranilate 3,4-dioxygenase, downstream enzyme | Links to quinolinic acid production |
| QPRT | Quinolinate phosphoribosyltransferase, downstream | Affects NAD+ synthesis |
| NADSYN1 | NAD+ synthetase, maintains NAD+ pool | Influences cofactor availability |
| NMNAT1 | Nicotinamide mononucleotide adenylyltransferase | Regulates NAD+ homeostasis |
| GAPDH | Glycolytic enzyme, NAD+ dependent | Model for NAD+ binding studies |
| ALDH1A1 | Aldehyde dehydrogenase family member | Comparative studies of mechanism |
| ALDH2 | Mitochondrial aldehyde dehydrogenase | Model for tetrameric assembly |
| Pseudomonas pseudoalcaligenes JS45 | Bacterial source of the enzyme | Biodegradation of 2-aminophenol |
| E. coli | Heterologous expression host | Recombinant enzyme production |
| Saccharomyces cerevisiae | Eukaryotic model for pathway engineering | Tryptophan catabolism studies |
| Drosophila melanogaster | Model for kynurenine pathway | Neurodegeneration research |
| Mus musculus | Mammalian model for ALDH8A1 | Knockout studies |
| Homo sapiens | Human relevance | Disease association studies |
| NAD+ | Essential cofactor | Redox balance and enzyme activity |
| NADH | Product and feedback inhibitor | Regulation of enzyme activity |
How Is aminomuconate-semialdehyde dehydrogenase (NAD+) activity Regulated?
The activity is regulated by the availability of NAD+ and the cellular redox state. Tetramerization is essential for cofactor binding, and post-translational modifications may affect assembly. In the kynurenine pathway, upstream enzymes such as KMO and KYNU control substrate supply, indirectly regulating flux through this step. Additionally, the pitcher-and-catcher mechanism ensures substrate fidelity, which can be modulated by mutations.
aminomuconate-semialdehyde dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALDH8A1 | Neurological disorders, metabolic imbalance | Knockout mice, patient-derived iPSCs |
| KMO | Huntington's disease, schizophrenia | Knockout cell lines, enzymatic assays |
| KYNU | Immune regulation, cancer | Overexpression models, CRISPR knock-in |
| HAAO | Quinolinic acid accumulation, neurotoxicity | Point-mutation models |
| QPRT | NAD+ deficiency disorders | Knockdown and rescue experiments |
Neurological Disorders
Dysregulation of the kynurenine pathway, including altered aminomuconate-semialdehyde dehydrogenase activity, has been implicated in neurodegenerative diseases such as Alzheimer's and Huntington's disease. Imbalances in neuroactive metabolites like quinolinic acid can lead to excitotoxicity.
Metabolic Disorders
Changes in NAD+ homeostasis due to impaired dehydrogenase activity may contribute to metabolic syndromes and mitochondrial dysfunction. The enzyme's role in redox balance links it to obesity and diabetes.
Cancer
Altered tryptophan catabolism is a hallmark of cancer, and enzymes in the kynurenine pathway are often overexpressed in tumors, promoting immune evasion. Targeting this activity could enhance immunotherapy.
From aminomuconate-semialdehyde dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALDH8A1 affect kynurenine pathway flux? | ALDH8A1 knockout cell line (CRISPR) |
| How does a point mutation in the active site alter catalysis? | Point-mutation knock-in via CRISPR |
| Can tagged ALDH8A1 reveal subcellular localization? | Knock-in of fluorescent tag |
| What is the effect of ALDH8A1 overexpression on NAD+ levels? | Overexpression cell model |
| Does tetramer disruption affect cofactor binding? | Site-directed mutagenesis and recombinant expression |
| Can small molecules modulate enzyme activity? | High-throughput screening with purified enzyme |
How to Study the aminomuconate-semialdehyde dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | Enzyme activity | Kinetic studies |
| X-ray crystallography | 3D structure | Mechanistic insights |
| CRISPR knockout | Gene function | Pathway analysis |
| LC-MS metabolomics | Metabolite levels | Flux analysis |
| Site-directed mutagenesis | Residue function | Active site mapping |
| Isothermal titration calorimetry | Binding affinity | Cofactor interaction |
| Size-exclusion chromatography | Oligomeric state | Tetramer assembly |
| RNA-seq | Gene expression | Pathway regulation |
Enzymatic Assays
Spectrophotometric assays monitoring NADH production at 340 nm are standard for measuring aminomuconate-semialdehyde dehydrogenase activity. These assays can be adapted for high-throughput screening.
Structural Biology
X-ray crystallography and cryo-EM have provided snapshots of the enzyme in action, revealing conformational changes and the pitcher-and-catcher mechanism. These methods are essential for understanding substrate specificity and tetramer assembly.
CRISPR-Based Functional Genomics
CRISPR knockout and knock-in models allow researchers to dissect the role of ALDH8A1 and related genes in cellular pathways. Pooled library screening can identify modifiers of enzyme activity.
Metabolomics and Flux Analysis
LC-MS-based metabolomics quantifies kynurenine pathway metabolites, providing insights into flux changes upon genetic manipulation. Isotope tracing can measure NAD+ turnover.
How CRISPR Can Be Used to Study GO:0047102 aminomuconate-semialdehyde dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of ALDH8A1 in human cell lines can abolish aminomuconate-semialdehyde dehydrogenase activity, leading to accumulation of upstream metabolites and altered NAD+ levels. This model is useful for studying the enzyme's role in kynurenine pathway flux and neurotoxicity.
Point Mutation
Introducing point mutations in the active site or tetramer interface via CRISPR can dissect the contribution of specific residues to catalysis and assembly. Such models help validate structural findings and identify disease-associated variants.
Knock-in
Knock-in of epitope tags or fluorescent proteins allows real-time tracking of enzyme localization and interactions. This approach can also be used to create reporter cell lines for high-content screening.
Overexpression
Overexpression of ALDH8A1 using CRISPR activation or lentiviral delivery can increase enzyme activity, enabling studies of metabolic burden and NAD+ depletion. This is valuable for testing therapeutic hypotheses in cancer and neurodegeneration.
How EDITGENE Supports aminomuconate-semialdehyde dehydrogenase (NAD+) activity Research
Researchers studying aminomuconate-semialdehyde dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides custom CRISPR cell models to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for aminomuconate-semialdehyde dehydrogenase (NAD+) activity research.
Frequently Asked Questions About aminomuconate-semialdehyde dehydrogenase (NAD+) activity
What is aminomuconate-semialdehyde dehydrogenase (NAD+) activity?
It is the enzyme activity defined by GO:0047102, catalyzing the NAD+-dependent oxidation of 2-aminomuconate semialdehyde to 2-aminomuconate in the kynurenine pathway.
What genes are involved in aminomuconate-semialdehyde dehydrogenase (NAD+) activity?
The human gene ALDH8A1 (ALDH12) encodes the enzyme, while upstream genes like KMO and KYNU regulate substrate supply.
What is the role of GO:0047102 in tryptophan catabolism?
It catalyzes a step in the kynurenine pathway, converting 2-aminomuconate semialdehyde to 2-aminomuconate, which is further degraded to acetyl-CoA.
How is aminomuconate-semialdehyde dehydrogenase (NAD+) activity regulated?
It is regulated by NAD+ availability, tetramer assembly, and upstream pathway enzymes.
What diseases are associated with aminomuconate-semialdehyde dehydrogenase (NAD+) activity?
Dysregulation has been linked to neurological disorders, metabolic syndromes, and cancer through altered kynurenine pathway flux.
What is the pitcher-and-catcher mechanism in this enzyme?
It is a substrate isomerization mechanism that ensures correct processing of 2-aminomuconate semialdehyde before dehydrogenation.
Why is tetramerization important for this enzyme?
The tetrameric assembly is required for efficient NAD+ binding and catalytic activity, as shown by structural and biochemical studies.
How can CRISPR be used to study aminomuconate-semialdehyde dehydrogenase (NAD+) activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of the enzyme in cells.
What methods measure aminomuconate-semialdehyde dehydrogenase (NAD+) activity?
Spectrophotometric NADH assays, crystallography, and metabolomics are commonly used.
What cell models are available for studying this activity?
EDITGENE provides knockout, point-mutation, knock-in, and overexpression cell lines for ALDH8A1 and related genes.
Conclusion
Aminomuconate-semialdehyde dehydrogenase (NAD+) activity (GO:0047102) is a key enzymatic step in the kynurenine pathway, linking tryptophan catabolism to NAD+ homeostasis and neuroactive metabolite production. Its complex regulation and tetrameric assembly make it an attractive target for mechanistic and disease research. Advances in CRISPR technology enable precise modeling of this activity in human cells, accelerating discoveries in neurobiology and metabolism.
References
- 1. Shi Q et al.. 2022. The tetrameric assembly of 2-aminomuconic 6-semialdehyde dehydrogenase is a functional requirement of cofactor NAD(+) binding.. Environ Microbiol 24(7):2994-3012 PMID: 34806815
- 2. Yang Y et al.. 2016. A Pitcher-and-Catcher Mechanism Drives Endogenous Substrate Isomerization by a Dehydrogenase in Kynurenine Metabolism.. J Biol Chem 291(51):26252-26261 PMID: 27810899
- 3. Davis I et al.. 2018. Reassignment of the human aldehyde dehydrogenase ALDH8A1 (ALDH12) to the kynurenine pathway in tryptophan catabolism.. J Biol Chem 293(25):9594-9603 PMID: 29703752
- 4. Huo L et al.. 2015. Crystallographic and spectroscopic snapshots reveal a dehydrogenase in action.. Nat Commun 6:5935 PMID: 25565451
- 5. He Z et al.. 1998. Purification, characterization, and sequence analysis of 2-aminomuconic 6-semialdehyde dehydrogenase from Pseudomonas pseudoalcaligenes JS45.. J Bacteriol 180(17):4591-5 PMID: 9721300
